Search Results

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd., signed a licensing agreement with Austria-based Marinomed Biotech AG, whereby Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® in China.

Shanghai Grit Biotechnology Co., Ltd. and Shandong Quangang Pharmaceutical Co., Ltd. announced the establishment of a formal strategic partnership to leverage both parties’ R&D capabilities in innovative T-cell therapy.

Guided Therapeutics, Inc. announced that it had signed a new agreement with the Company’s Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation.

Synergy Pharmaceuticals Inc. announced that the company has entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin) providing Luoxin exclusive rights to develop and commercialize Synergy’s lead product TRULANCE® (plecanatide)

PharmaBlock Sciences, Inc. has announced the successful attainment of Energy Management System Certification for its headquarters and R&D center in Nanjing, as well as its manufacturing facilities in Zhejiang and Shandong, China.

ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.

Shineco, Inc. announced that on March 4, 2022, the Company has signed a strategic cooperation framework agreement on Shineco’s Weifang Life Science Industrial Park Project with the Development Service Center of Weifang Binhai Science and Technology Innovation Park in Shandong Province to build one of China’s first city-level tumor classification diagnosis and treatment centers and an online telemedicine service platform, which would constitute Shineco’s tumor diagnosis and treatment platform.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.